CN110638827A - Application of NADH and its salt in preparing skin pigment inhibitor - Google Patents
Application of NADH and its salt in preparing skin pigment inhibitor Download PDFInfo
- Publication number
- CN110638827A CN110638827A CN201910988662.7A CN201910988662A CN110638827A CN 110638827 A CN110638827 A CN 110638827A CN 201910988662 A CN201910988662 A CN 201910988662A CN 110638827 A CN110638827 A CN 110638827A
- Authority
- CN
- China
- Prior art keywords
- nadh
- parts
- extract
- skin
- nmn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title claims abstract description 46
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title claims abstract description 45
- 150000003839 salts Chemical class 0.000 title claims abstract description 16
- 239000000049 pigment Substances 0.000 title claims abstract description 11
- 239000003112 inhibitor Substances 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 208000012641 Pigmentation disease Diseases 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000002417 nutraceutical Substances 0.000 claims description 6
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000132012 Atractylodes Species 0.000 claims description 3
- 240000006766 Cornus mas Species 0.000 claims description 3
- 235000004837 Polyporus umbellatus Nutrition 0.000 claims description 3
- 244000197580 Poria cocos Species 0.000 claims description 3
- 235000008599 Poria cocos Nutrition 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 241001061264 Astragalus Species 0.000 claims description 2
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims description 2
- 230000005778 DNA damage Effects 0.000 claims description 2
- 231100000277 DNA damage Toxicity 0.000 claims description 2
- 235000002897 Grifola umbellata Nutrition 0.000 claims description 2
- 235000006533 astragalus Nutrition 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000000852 hydrogen donor Substances 0.000 claims description 2
- 229940069445 licorice extract Drugs 0.000 claims description 2
- 244000097863 Grifola umbellata Species 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 208000017520 skin disease Diseases 0.000 abstract description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 244000171085 Polyporus umbellatus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The embodiment of the invention discloses an application of NADH and a salt thereof in preparing a skin pigment inhibitor. NADH and/or pharmacologically acceptable salts thereof can be used for preparing pharmaceutical compositions, health care compositions and cosmetic compositions for inhibiting skin pigment production. The NADH composition product of the present invention causes no side effects, is effective in inhibiting pigmentation in the skin, and is useful for preventing or treating skin diseases associated with pigmentation.
Description
Technical Field
The invention relates to the technical field of medicines, health products or cosmetics, in particular to application of NADH in preparation of a skin-color pigment inhibitor.
Background
When skin is exposed to ultraviolet radiation, melanin is produced to protect skin cells from ultraviolet radiation. The generated melanin absorbs ultraviolet rays, thereby preventing the ultraviolet rays from penetrating into the skin. Thus, melanin is an important pigment for protecting skin cells, but if it is excessively produced, it is deposited on the skin and causes freckles. Freckles tend to be rejected from a cosmetic point of view, consumers are very interested in skin whitening agents, and ingredients having a whitening effect to inhibit the deposition of melanin on the skin are also actively developed. For example, it has been reported that niacinamide has an effect of inhibiting pigmentation caused by ultraviolet irradiation by inhibiting the transfer of melanosomes from melanocytes to keratinocytes, and oral intake of niacinamide can prevent pigmentation and inhibit the increase of freckles and chloasma caused by ultraviolet irradiation.
However, there has not been any study of the effect of NADH, especially reduced NADH, on skin pigmentation.
Disclosure of Invention
In view of the above problems, it is an object of the present invention to provide the use of NADH and its salts for the preparation of skin pigmentation inhibitors.
In the present invention, said NADH especially refers to beta-NADH, reduced Nicotinamide adenine dinucleotide (Nicotinamide adenine dinucleotide).
In one embodiment of the invention, said NADH and salts thereof are administered parenterally, including orally, and parenterally, including by injection.
In one embodiment of the invention, the single dose of NADH is 0.1-10 mg/kg, preferably 0.1-4 mg/kg, when orally administered. The daily frequency is 1-3 times, and the daily dosage is 0.1-30 mg/kg, preferably 0.1-12 mg/kg, more preferably 0.4-2 mg/kg. The single dose of NADH in the injection is 0.1-2 mg/kg, preferably 0.1-1 mg/kg. Wherein kg is the weight unit of the subject individual.
In one embodiment of the present invention, NADH is used in combination with excipients to make various dosage forms including, but not limited to, tablets, granules, powders, capsules, liquids, emulsions, lyophilized preparations, injections, suppositories, ointments, gels, inhalants, nasal preparations, enteral medicines, sprays, and the like.
The second technical object of the present invention is to provide a pharmaceutical composition or health care product composition for inhibiting skin pigmentation, which comprises NADH and/or a pharmacologically acceptable salt thereof as the only active ingredient.
In one embodiment of the present invention, the pharmaceutical composition or the nutraceutical composition further comprises pharmaceutically or dietetically acceptable excipients.
In one embodiment of the present invention, the pharmaceutical composition or the health product composition is prepared by mixing NADH with conventional pharmaceutical or dietary excipients and making into various dosage forms by a conventional method.
In one embodiment of the present invention, the pharmaceutical composition or the nutraceutical composition further comprises NMN (β -Nicotinamide monofulotide, β -Nicotinamide Mononucleotide) as an adjuvant to assist or enhance the pigment inhibition effect of NADH. The weight ratio of NADH or its salt to NMN in the composition is (1-10) to (1-10), preferably (1-3) to (1-3).
In one embodiment of the present invention, the pharmaceutical composition further comprises the following components as auxiliary active ingredients: atractylodis rhizoma extract, Poria extract, Corni fructus extract, Polyporus extract, semen astragali Complanati extract and Glycyrrhrizae radix extract.
In a more specific embodiment of the present invention, the pharmaceutical composition comprises the following components by weight: 1-10 parts of NADH, 1-10 parts of NMN, 1-10 parts of bighead atractylodes rhizome extract, 1-10 parts of poria cocos extract, 1-10 parts of dogwood extract, 1-10 parts of grifola umbellata extract, 1-10 parts of flatstem milkvetch seed extract and 1-10 parts of licorice extract.
In one embodiment of the present invention, the above pharmaceutical composition is preferably administered orally, by injection or transdermally.
In one embodiment of the present invention, the nutraceutical composition is administered by gastrointestinal administration or parenteral administration, wherein gastrointestinal administration includes oral administration, and parenteral administration includes injection.
It is a further object of the present invention to provide a cosmetic composition for inhibiting skin pigmentation, which comprises NADH and/or a pharmacologically acceptable salt thereof as the only active ingredient.
In one embodiment of the present invention, the cosmetic composition further comprises NMN as an adjuvant, and the weight ratio of NADH or its salt to NMN is (1-10) to (1-10).
In one embodiment of the present invention, the cosmetic composition further comprises a cosmetically acceptable adjuvant.
In one embodiment of the present invention, the cosmetic composition is administered transdermally.
The embodiment of the invention has the following beneficial effects:
ultraviolet light is an increasingly leading cause of oxidative damage to the skin. Ultraviolet B can directly act on DNA of skin cells, and ultraviolet a changes nuclear DNA and mitochondrial DNA mainly by generating oxygen radicals harmful to the human body, so that oxidative damage is always accompanied by aging and causes various problems of the skin such as yellowing, dullness, pigmentation of skin. And the ultraviolet rays can also cause the increase of melanocytes and further increase the skin pigmentation. In the technical scheme of the invention, nicotinamide adenine dinucleotide can increase the level of NAD + in a human body, so that skin DNA damage caused by Ultraviolet (UV) light is inhibited or prevented. And NADH is used as a natural hydrogen donor in the human body, and can further eliminate harmful oxygen free radicals in the human body. The invention uses NADH as an active ingredient in preparing medicines, health care products or cosmetics for inhibiting skin pigments, and the specific dosage can be determined according to the severity of the disease condition, the application route and related factors. The use of the composition product of the present invention causes no side effects, is effective in inhibiting pigmentation in the skin, and is useful for preventing or treating skin diseases associated with pigmentation.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to specific embodiments, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
In vitro experiment of the effect of NADH on the amount of melanin produced by cells:
adjusting the concentration of human melanoma cell A375 (purchased from Shenzhen university) to 1 × 105one/mL, seeded in 6-well plates, 2mL per well. After the adherence, the cells are grouped into 25-200 mu mol/L-1NADH treatment (sample group) of (1), control group with 200. mu. mol. L-1Native human type I collagen was treated, the blank was treated with normal saline, washed 3 times with pre-cooled PBS after 48h and scraped off and collected in sterile EP tubes. The melanin content was determined using the method of Tsuboi (1998): centrifuging at 1500rpm for 5min, discarding supernatant, lysing cells with 0.5mL of 1 mol. L-1NaOH solution containing 10% DMSO, ultrasonically crushing for 30min, performing water bath at 90 ℃ for 2h to completely lyse cell aggregates, centrifuging at 3000rpm for 15min, taking supernatant to a 96-well plate, measuring A value at 450nm of an enzyme labeling instrument, and calculating the relative content of melanin in cells, wherein the result is shown in Table 1.
Relative melanin synthesis content, a1/a0, where Al is the absorbance of the sample set and a0 is the absorbance of the blank set.
Table 1 relative content of melanin synthesis in each group
| Group of | Relative content of melanin synthesis |
| Blank group | 1 |
| Control group | 0.58±0.62 |
| 25μmol·L-1NADH processing group | 0.87±0.21 |
| 50μmol·L-1NADH processing group | 0.79±0.57 |
| 100μmol·L-1NADH processing group | 0.64±0.34 |
| 200μmol·L-1NADH processing group | 0.51±0.83 |
As shown in Table 1, 25 to 200. mu. mol. L-1Concentration-dependent inhibition of melanin synthesis in melanoma cells (P < 0.05) with 200. mu. mol. L48 hours after NADH treatment of the melanoma cells in the range-1NADH has strongest inhibitory effect on melanin synthesis, and melanin content is reduced by about 49% (0.51 + -0.83; P)<0.01). Indicating that NADH has a significant effect in inhibiting melanin production by cells.
Example 2
Human trials of NADH in inhibiting skin melanin and reducing skin damage:
healthy 18 women aged 30-40 years were used as subjects, and randomized into 6 groups of 3 people each. Experimental group 4 group: within one hour before measurement respectively at the measurement partCoating the surface with 25-200 mu mol per liter-1NADH in the range, once per day. Control group 1: applying 200 μmol/L by the same method-1Kojic acid (1). Blank group 1 group: only physiological saline was applied. An opaque adhesive tape having a hole with a diameter of 1.5cm is attached to the upper arm of a subject, and ultraviolet B rays with a Minimum Erythema Dose (MED) of about 1.5 to 2 times of that of each subject are irradiated to induce skin blackening. Changes over time in the melanin index and erythema index after UV irradiation were measured with a spectrocolorimeter CM-1000.
The following measurements were made according to Mapekun et al "evaluation and analysis method of cosmetic functionality" (Chinese light industry Press, 1998): a light source is selected based on the absorption spectrum of hemoglobin and melanin in the skin by utilizing the specific reflection spectral characteristics of a pigment constituting skin color, 568nm and 655nm are used as two specific wavelengths, and the diffusion illumination/vertical light receiving method is referred to Japanese Industrial Standard JIS Z8722. The intensity of the reflected light was measured with a spectrocolorimeter (CM-1000) using a pulse neon lamp as a light source. The contact measurement diameter was 8 mm. The degree of erythema and pigmentation was calculated as an erythema index and a melanin index using the following formulas.
Erythema index ═ lg (1/G) -lg (1/R)
Melanin index lg (1/R)
In the formula: g-intensity of green light reflected, R-intensity of red light reflected.
The results are shown in tables 2 and 3, in which the numerical values represent the mean values of the measurements.
TABLE 2 Melanin index Table
| Group of | Day 0 | 7 days | 14 days | 21 days | 28 days | For 56 days |
| Blank group | 50.2 | 53.6 | 57.1 | 62.5 | 65.7 | 69.5 |
| Control group | 50.2 | 51.7 | 55.4 | 58.1 | 61.9 | 65.3 |
| 25μmol·L-1NADH of | 50.2 | 51.2 | 54.7 | 57.8 | 60.6 | 63.7 |
| 50μmol·L-1NADH of | 50.2 | 51.0 | 54.1 | 57.3 | 60.2 | 63.2 |
| 100μmol·L-1NADH of | 50.2 | 50.9 | 52.9 | 55.4 | 57.7 | 59.4 |
| 200μmol·L-1NADH of | 50.2 | 50.5 | 52.0 | 54.1 | 56.0 | 58.6 |
TABLE 3 erythema index values
| Group of | Day 0 | 7 days | 14 days | 21 days | 28 days | For 56 days |
| Blank group | 10.5 | 11.7 | 12.5 | 13.8 | 14.6 | 16.8 |
| Control group | 10.5 | 11.5 | 12.3 | 13.1 | 13.9 | 15.3 |
| 25μmol·L-1NADH of | 10.5 | 11.3 | 12.0 | 12.6 | 13.5 | 14.7 |
| 50μmol·L-1NADH of | 10.5 | 11.1 | 11.6 | 12.2 | 13.1 | 14.0 |
| 100μmol·L-1NADH of | 10.5 | 10.8 | 11.0 | 11.7 | 12.8 | 13.7 |
| 200μmol·L-1NADH of | 10.5 | 10.6 | 10.8 | 11.3 | 12.0 | 12.9 |
As can be seen from the data in Table 2, NADH is effective in inhibiting skin melanin; the results in Table 3 show that NADH can reduce the damage of ultraviolet rays to the skin and protect the skin.
Example 3
Discloses a pharmaceutical composition for inhibiting skin pigment by taking NADH as an active component:
mixing 5 parts of bighead atractylodes rhizome extract, 1 part of poria cocos extract, 3 parts of dogwood fruit extract, 4 parts of polyporus umbellatus extract, 1 part of semen astragali complanati extract and 1 part of liquorice root extract, adding 8 times of water by mass to dissolve the mixture, stirring the mixture uniformly, adding 5 parts of NADH and 5 parts of NMN, stirring the mixture uniformly and fully at room temperature, heating the mixture to 50 ℃, and concentrating the mixture in vacuum to obtain the composition. The composition is made into tablet with pharmaceutical adjuvants by conventional method.
The above disclosure is only for the purpose of illustrating the preferred embodiments of the present invention, and it is therefore to be understood that the invention is not limited by the scope of the appended claims.
Claims (10)
- The use of NADH and its salts in the preparation of skin pigment inhibitors.
- 2. The use of claim 1 wherein said NADH and salts thereof are administered parenterally, including orally, and parenterally, including by injection.
- 3. The use according to claim 2, wherein the single dose of NADH is 0.1 to 10mg/kg for oral administration and 0.1 to 2mg/kg for injection administration, and is administered 1 to 3 times per day.
- 4. The use of claim 1, wherein NADH as a skin pigmentation inhibitor is based on NADH increasing NAD + levels in the human body to inhibit or prevent DNA damage in the skin caused by uv light, and NADH acting as a natural hydrogen donor in the human body to further scavenge harmful oxygen free radicals in the human body.
- 5. A cosmetic composition for inhibiting skin pigmentation comprising NADH and/or a pharmacologically acceptable salt thereof as the only active ingredient.
- 6. The cosmetic composition according to claim 5, further comprising NMN as an adjuvant, wherein the weight ratio of NADH or a salt thereof to NMN is (1-10) to (1-10).
- 7. The cosmetic composition of claim 5, further comprising cosmetically acceptable adjuvants.
- 8. A pharmaceutical composition or nutraceutical composition for inhibiting skin pigmentation, characterized in that it has NADH and/or a pharmacologically acceptable salt thereof as the sole active ingredient.
- 9. The pharmaceutical or nutraceutical composition of claim 8, further comprising NMN as an adjuvant, wherein the weight ratio of NADH or its salt to NMN is (1-10) to (1-10).
- 10. The pharmaceutical composition or nutraceutical composition of claim 8, wherein the pharmaceutical composition comprises the following components in parts by weight: 1-10 parts of NADH, 1-10 parts of NMN, 1-10 parts of bighead atractylodes rhizome extract, 1-10 parts of poria cocos extract, 1-10 parts of dogwood extract, 1-10 parts of grifola umbellata extract, 1-10 parts of flatstem milkvetch seed extract and 1-10 parts of licorice extract.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910988662.7A CN110638827A (en) | 2019-10-17 | 2019-10-17 | Application of NADH and its salt in preparing skin pigment inhibitor |
| PCT/CN2020/118815 WO2021073426A1 (en) | 2019-10-17 | 2020-09-29 | Application of nadh and salt thereof in preparation of skin pigment inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910988662.7A CN110638827A (en) | 2019-10-17 | 2019-10-17 | Application of NADH and its salt in preparing skin pigment inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110638827A true CN110638827A (en) | 2020-01-03 |
Family
ID=68994326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910988662.7A Pending CN110638827A (en) | 2019-10-17 | 2019-10-17 | Application of NADH and its salt in preparing skin pigment inhibitor |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110638827A (en) |
| WO (1) | WO2021073426A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021073426A1 (en) * | 2019-10-17 | 2021-04-22 | 泓博元生命科技（深圳）有限公司 | Application of nadh and salt thereof in preparation of skin pigment inhibitor |
| CN112791008A (en) * | 2021-01-29 | 2021-05-14 | 中粮集团有限公司 | Application of coenzyme in anti-aging beauty skin care product, skin care product containing coenzyme and preparation method of skin care product |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1059839A (en) * | 1996-08-21 | 1998-03-03 | Noevir Co Ltd | Preparation for external use for skin |
| JP2001048773A (en) * | 1999-08-10 | 2001-02-20 | Naris Cosmetics Co Ltd | Cosmetic |
| CN108969396A (en) * | 2018-10-09 | 2018-12-11 | 泓博元生命科技（深圳）有限公司 | A kind of gel skin care item and preparation method thereof containing NMN |
| CN109350557A (en) * | 2018-05-25 | 2019-02-19 | 泓博元生命科技（深圳）有限公司 | Anti-apolexis composition, skin care item comprising NADH and ceramide and the preparation method and application thereof |
| CN109985056A (en) * | 2013-10-30 | 2019-07-09 | 可劳迈戴斯有限公司 | Nicotinamide riboside composition for the local use in treatment skin disease |
| CN110237089A (en) * | 2019-06-19 | 2019-09-17 | 泓博元生命科技（深圳）有限公司 | The application of NADH and/or NMN prevention and treatment male erectile dysfunction |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352513B (en) * | 2014-11-14 | 2017-04-05 | 邦泰生物工程(深圳)有限公司 | NADH or salt are in the application for preparing treatment phenylketonuria disease drug or health products |
| CN109646423A (en) * | 2018-12-03 | 2019-04-19 | 泓博元生命科技（深圳）有限公司 | Boiomacromolecule nanosphere containing NADH and the preparation method and application thereof |
| CN110638827A (en) * | 2019-10-17 | 2020-01-03 | 泓博元生命科技（深圳）有限公司 | Application of NADH and its salt in preparing skin pigment inhibitor |
-
2019
- 2019-10-17 CN CN201910988662.7A patent/CN110638827A/en active Pending
-
2020
- 2020-09-29 WO PCT/CN2020/118815 patent/WO2021073426A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1059839A (en) * | 1996-08-21 | 1998-03-03 | Noevir Co Ltd | Preparation for external use for skin |
| JP2001048773A (en) * | 1999-08-10 | 2001-02-20 | Naris Cosmetics Co Ltd | Cosmetic |
| CN109985056A (en) * | 2013-10-30 | 2019-07-09 | 可劳迈戴斯有限公司 | Nicotinamide riboside composition for the local use in treatment skin disease |
| CN109350557A (en) * | 2018-05-25 | 2019-02-19 | 泓博元生命科技（深圳）有限公司 | Anti-apolexis composition, skin care item comprising NADH and ceramide and the preparation method and application thereof |
| CN108969396A (en) * | 2018-10-09 | 2018-12-11 | 泓博元生命科技（深圳）有限公司 | A kind of gel skin care item and preparation method thereof containing NMN |
| CN110237089A (en) * | 2019-06-19 | 2019-09-17 | 泓博元生命科技（深圳）有限公司 | The application of NADH and/or NMN prevention and treatment male erectile dysfunction |
Non-Patent Citations (3)
| Title |
|---|
| 史晓凤等: "皮肤的光学性质研究", 《发光学报》 * |
| 彭冠杰，郭清泉主编: "《美白化妆品科学与技术》", 30 June 2019 * |
| 朱海琴等: "烟酰胺在皮肤局部外用中的进展", 《临床皮肤科杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021073426A1 (en) * | 2019-10-17 | 2021-04-22 | 泓博元生命科技（深圳）有限公司 | Application of nadh and salt thereof in preparation of skin pigment inhibitor |
| CN112791008A (en) * | 2021-01-29 | 2021-05-14 | 中粮集团有限公司 | Application of coenzyme in anti-aging beauty skin care product, skin care product containing coenzyme and preparation method of skin care product |
| CN112791008B (en) * | 2021-01-29 | 2022-06-21 | 中粮集团有限公司 | Application of coenzyme in anti-aging beauty skin care product, skin care product containing coenzyme and preparation method of skin care product |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021073426A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5804168A (en) | Pharmaceutical compositions and methods for protecting and treating sun damaged skin | |
| US20120258060A1 (en) | Methods for protecting the skin from radiation insults | |
| Mathews-Roth | Plasma concentrations of carotenoids after large doses of beta-carotene | |
| WO2009067095A1 (en) | Topical cosmetic skin lightening compositions and methods of use thereof | |
| US20090028895A1 (en) | Methods and compositions for reducing facial lines and wrinkles | |
| KR20060130631A (en) | Holistic composition and method for reducing skin pigmentation | |
| KR101902911B1 (en) | Composition for improving human skin cell injury by UV-B comprising the extract of Hydrangea serrata | |
| CN110638827A (en) | Application of NADH and its salt in preparing skin pigment inhibitor | |
| KR20060114774A (en) | Cosmetic composition containing (20s)-ginsenoside rg3 for preventing and improving skin wrinkles | |
| US20100178286A1 (en) | Methods and compositions for reducing facial lines and wrinkles | |
| KR20100124132A (en) | Anti-wrinkle cosmetic composition containing oriental herb extract treated by enzyme and its extraction method | |
| CN113425639A (en) | Antioxidant composition, application thereof and product | |
| US20100166683A1 (en) | Composition of external preparation for uv-protection comprising rehmannia glutinosa extracts | |
| KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
| KR101998215B1 (en) | Method for improving skin whitening effect in the red ginseng extract and composition for skin whitening using the same | |
| US11110117B2 (en) | Skin preparation composition for external use containing complex hyaluronic acid | |
| CN109925248B (en) | A skin care composition containing phloretin and Panax notoginsenosides with skin photoaging resisting effect | |
| CN106729150A (en) | A kind of pharmaceutical formulation of skin-whitening and speckle eliminating | |
| KR20010093861A (en) | Whitening composition including the extract of the fruits of Melia azedarach or M. toosendan | |
| KR20110043019A (en) | Composition for skin whitening consist of plant exract and cosmetic compostion comprising the plant extract compostion | |
| CN110302111A (en) | A kind of anti-oxidant gel mask, preparation method and application | |
| CN108836927A (en) | A kind of spot-eliminating composition | |
| KR20020008268A (en) | Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois | |
| CN115154360B (en) | Composition with whitening, freckle removing and moisturizing effects and application thereof | |
| WO2015126226A1 (en) | Composition containing extract derived from green tea leafstalk for skin whitening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200103 |